Taho Pharmaceuticals Ltd. (TPE:6467)
204.00
-20.50 (-9.13%)
At close: Nov 19, 2026
Taho Pharmaceuticals Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 98.68 | 339.98 | 245.87 | 151.71 | 74.3 | 39.22 |
Short-Term Investments | 150 | 50 | 250 | 78.07 | 32 | 42 |
Cash & Short-Term Investments | 248.68 | 389.98 | 495.87 | 229.77 | 106.3 | 81.22 |
Cash Growth | -36.23% | -21.36% | 115.81% | 116.16% | 30.87% | -36.85% |
Accounts Receivable | 2.92 | 0.16 | - | - | - | 1.39 |
Other Receivables | 1.09 | 0.65 | 0.87 | 0.29 | 0.03 | 0.01 |
Receivables | 4.01 | 0.8 | 0.87 | 0.29 | 0.03 | 1.39 |
Prepaid Expenses | 1.66 | 2.85 | 2.18 | 3.24 | 4.96 | 0.64 |
Other Current Assets | - | - | - | - | - | 0.15 |
Total Current Assets | 254.35 | 393.62 | 498.92 | 233.31 | 111.29 | 83.41 |
Property, Plant & Equipment | 22.28 | 22.45 | 24.86 | 23.55 | 4.33 | 12.35 |
Long-Term Investments | 8.08 | 7.86 | 8.01 | - | - | - |
Other Intangible Assets | 0.58 | 0.74 | - | - | - | - |
Other Long-Term Assets | 30.2 | 30.92 | 28.91 | 26.34 | 22.93 | 13.47 |
Total Assets | 315.49 | 455.6 | 560.7 | 283.2 | 138.54 | 109.23 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | - | 17.73 | 24.74 | 21.53 | 10.5 | 3.63 |
Current Portion of Leases | 5.71 | 5.55 | 5.34 | 4.97 | - | 4.92 |
Current Unearned Revenue | - | - | 0.71 | - | 0.19 | 1.85 |
Other Current Liabilities | 12.73 | 2.76 | 2.28 | 33.2 | 35.8 | 2.6 |
Total Current Liabilities | 18.44 | 26.04 | 33.06 | 59.7 | 46.49 | 12.99 |
Long-Term Leases | 1.46 | 5.77 | 11.31 | 16.65 | - | - |
Other Long-Term Liabilities | 0.07 | 0.09 | 0.12 | 0.15 | - | 32 |
Total Liabilities | 19.97 | 31.9 | 44.5 | 76.5 | 46.49 | 44.99 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 524.09 | 523.56 | 512.16 | 423.07 | 372.97 | 346.56 |
Additional Paid-In Capital | 39.7 | 114.69 | 388.42 | 256.19 | 70.96 | 2.62 |
Retained Earnings | -268.22 | -214.4 | -384.38 | -472.57 | -351.89 | -285.59 |
Comprehensive Income & Other | -0.05 | -0.15 | - | - | - | 0.64 |
Shareholders' Equity | 295.51 | 423.7 | 516.2 | 206.69 | 92.05 | 64.23 |
Total Liabilities & Equity | 315.49 | 455.6 | 560.7 | 283.2 | 138.54 | 109.23 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 7.17 | 11.31 | 16.65 | 21.62 | - | 4.92 |
Net Cash (Debt) | 241.5 | 378.66 | 479.22 | 208.15 | 106.3 | 76.31 |
Net Cash Growth | -36.22% | -20.98% | 130.22% | 95.82% | 39.30% | -40.26% |
Net Cash Per Share | 4.63 | 7.36 | 10.56 | 5.37 | 2.96 | 2.20 |
Filing Date Shares Outstanding | 52.37 | 52.36 | 51.22 | 51.22 | 37.3 | 34.66 |
Total Common Shares Outstanding | 52.37 | 52.36 | 51.22 | 51.22 | 37.3 | 34.66 |
Working Capital | 235.91 | 367.58 | 465.86 | 173.61 | 64.79 | 70.41 |
Book Value Per Share | 5.64 | 8.09 | 10.08 | 4.04 | 2.47 | 1.85 |
Tangible Book Value | 294.94 | 422.96 | 516.2 | 206.69 | 92.05 | 64.23 |
Tangible Book Value Per Share | 5.63 | 8.08 | 10.08 | 4.04 | 2.47 | 1.85 |
Machinery | - | 62.3 | 59.45 | 52.84 | 54.42 | 53.77 |
Leasehold Improvements | - | 17.25 | 14.03 | 13.81 | 13.75 | 13.71 |